The U.S. Food and Drug Administration (FDA) has approved a new starting dosage regimen for the subcutaneous (under the skin) ...
The FDA approved a new starting dosage regimen for the subcutaneous formulation of lecanemab (Leqembi Iqlik) to treat adults ...
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, ...
The FDA has approved a subcutaneous version of isatuximab (Sarclisa Escena, Sanofi-Aventis) for several multiple myeloma (MM) ...
Rituximab is noninferior to ocrelizumab in suppressing disease activity in newly diagnosed multiple sclerosis, with a similar incidence of adverse events, a new trial shows.
Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according ...
The U.S. Food and Drug Administration said on Friday it has approved Sanofi's blood cancer drug, Sarclisa, which can be given under the skin through a wearable injector, offering multiple ...
Apertura has entered a cooperative research and development agreement (CRADA) with various NIH institutes for a gene therapy ...
FDA approves subcutaneous isatuximab-irfc for multiple myeloma indications, offering an efficient delivery alternative to intravenous administration. The US Food and Drug Administration (FDA) has ...
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement ...
As a third-year internal medicine resident in 1988, I studied every person over 65 who entered our hospital emergency room ...
The FDA's Office of Prescription Drug Promotion issued an untitled letter to Lundbeck over claims on its webpages for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results